NVCR - Novocure announces BAG to add Optune+ temozolomide for treatment in newly diagnosed brain cancer patients in Switzerland

The Swiss Federal Office of Public Health ((BAG)) has added Novocure's (NVCR) Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma ((GBM)), effective April 1, 2021.The List of Remedies and Equipment defines which medical devices are covered by compulsory health insurance in Switzerland. Optune is a noninvasive, antimitotic cancer treatment that delivers Tumor Treating Fields using electric fields to disrupt cell division."National reimbursement of Optune for newly diagnosed GBM patients in Switzerland represents an incredible effort by our team to expand access to our therapy as well as an increased understanding of the benefits of our therapy among health insurers," says Pritesh Shah, Novocure’s Chief Commercial Officer.

For further details see:

Novocure announces BAG to add Optune+ temozolomide for treatment in newly diagnosed brain cancer patients in Switzerland